Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Corey J Langer

Showing results (201-210 of 225) with videos related to

Pageof 23
Sort By:
International Journal of Radiation Oncology, Biology, Physics|August 24, 2023
Pneumonitis Rates Before and After Adoption of Immunotherapy Consolidation in Patients With Locally Advanced Non-Small Cell Lung Cancer Treated With Concurrent ChemoradiationNikhil Yegya-Raman, Cole Friedes, Sang Ho Lee, et al.
JAMA Network Open|March 10, 2023
Clinical Outcomes Associated With Pembrolizumab Monotherapy Among Adults With Diffuse Malignant Peritoneal MesotheliomaMelina E Marmarelis, Xiao Wang, Leonid Roshkovan, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 23, 2019
Brigatinib in Crizotinib-Refractory ALK+ NSCLC: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA TrialRudolf M Huber, Karin H Hansen, Luis Paz-Ares Rodríguez, et al.
JCO Precision Oncology|June 7, 2021
Serial Monitoring of Circulating Tumor DNA by Next-Generation Gene Sequencing as a Biomarker of Response and Survival in Patients With Advanced NSCLC Receiving Pembrolizumab-Based TherapyJeffrey C Thompson, Erica L Carpenter, Benjamin A Silva, et al.
Science (New York, N.Y.)|June 20, 2024
Combined JAK inhibition and PD-1 immunotherapy for non-small cell lung cancer patientsDivij Mathew, Melina E Marmarelis, Caitlin Foley, et al.
JTO Clinical and Research Reports|April 8, 2022
Plasma Genotyping at the Time of Diagnostic Tissue Biopsy Decreases Time-to-Treatment in Patients With Advanced NSCLC-Results From a Prospective Pilot StudyJeffrey C Thompson, Charu Aggarwal, Janeline Wong, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|July 4, 2006
Non-small cell lung cancer clinical practice guidelines in oncologyDavid S Ettinger, Gerold Bepler, Raphael Bueno, et al.
Clinical Lung Cancer|April 19, 2023
Utilization and Factors Precluding Receipt of Checkpoint Inhibitor Consolidation for Stage III NSCLC in a Large US Academic Health SystemNikhil Yegya-Raman, Cole Friedes, Lova Sun, et al.
Journal of Geriatric Oncology|April 5, 2021
The impact of age on outcome in phase III NRG Oncology/RTOG trials of radiotherapy (XRT) +/- systemic therapy in locally advanced head and neck cancerJulie A Kish, Qiang Zhang, Corey J Langer, et al.
International Journal of Radiation Oncology, Biology, Physics|August 31, 2023
Phase 2 Trial of Consolidation Pembrolizumab After Proton Reirradiation for Thoracic Recurrences of Non-Small Cell Lung CancerNikhil Yegya-Raman, Abigail T Berman, Christine A Ciunci, et al.
Pageof 23

Showing results (201-210 of 225) with videos related to

Sort By:
Pageof 23
International Journal of Radiation Oncology, Biology, Physics|August 24, 2023
Pneumonitis Rates Before and After Adoption of Immunotherapy Consolidation in Patients With Locally Advanced Non-Small Cell Lung Cancer Treated With Concurrent ChemoradiationNikhil Yegya-Raman, Cole Friedes, Sang Ho Lee, et al.
JAMA Network Open|March 10, 2023
Clinical Outcomes Associated With Pembrolizumab Monotherapy Among Adults With Diffuse Malignant Peritoneal MesotheliomaMelina E Marmarelis, Xiao Wang, Leonid Roshkovan, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 23, 2019
Brigatinib in Crizotinib-Refractory ALK+ NSCLC: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA TrialRudolf M Huber, Karin H Hansen, Luis Paz-Ares Rodríguez, et al.
JCO Precision Oncology|June 7, 2021
Serial Monitoring of Circulating Tumor DNA by Next-Generation Gene Sequencing as a Biomarker of Response and Survival in Patients With Advanced NSCLC Receiving Pembrolizumab-Based TherapyJeffrey C Thompson, Erica L Carpenter, Benjamin A Silva, et al.
Science (New York, N.Y.)|June 20, 2024
Combined JAK inhibition and PD-1 immunotherapy for non-small cell lung cancer patientsDivij Mathew, Melina E Marmarelis, Caitlin Foley, et al.
JTO Clinical and Research Reports|April 8, 2022
Plasma Genotyping at the Time of Diagnostic Tissue Biopsy Decreases Time-to-Treatment in Patients With Advanced NSCLC-Results From a Prospective Pilot StudyJeffrey C Thompson, Charu Aggarwal, Janeline Wong, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|July 4, 2006
Non-small cell lung cancer clinical practice guidelines in oncologyDavid S Ettinger, Gerold Bepler, Raphael Bueno, et al.
Clinical Lung Cancer|April 19, 2023
Utilization and Factors Precluding Receipt of Checkpoint Inhibitor Consolidation for Stage III NSCLC in a Large US Academic Health SystemNikhil Yegya-Raman, Cole Friedes, Lova Sun, et al.
Journal of Geriatric Oncology|April 5, 2021
The impact of age on outcome in phase III NRG Oncology/RTOG trials of radiotherapy (XRT) +/- systemic therapy in locally advanced head and neck cancerJulie A Kish, Qiang Zhang, Corey J Langer, et al.
International Journal of Radiation Oncology, Biology, Physics|August 31, 2023
Phase 2 Trial of Consolidation Pembrolizumab After Proton Reirradiation for Thoracic Recurrences of Non-Small Cell Lung CancerNikhil Yegya-Raman, Abigail T Berman, Christine A Ciunci, et al.
Pageof 23